VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates ...
VERO BEACH, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today provided ...
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of ...
Processa Pharmaceuticals Inc. stock grades by Barron's. View PCSA fundamental and sentiment analysis powered by MarketGrader.
David Young, PharmD, PhD, Founder and President, Research and Development, of Processa Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company's ...
The average one-year price target for Processa Pharmaceuticals (NasdaqCM:PCSA) has been revised to $25.50 / share. This is an increase of 2,400.00% from the prior estimate of $1.02 dated December 3, ...
David Young, PharmD, PhD, Founder and President, Research and Development, of Processa Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company’s ...
ORLANDO, FL / ACCESS Newswire / December 26, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results